ALK and non-small cell lung carcinoma: For instance, the LCMC3 study of neoadjuvant atezolizumab in patients with resectable stage IB-IIIB NSCLC with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genetic aberrations attained a 21% of MPR at the time of resection and a pCR of 7%, while the use of atezolizumab in another neoadjuvant study yielded an MPR rate of only 13% and a pCR of 7%.